As substitution therapy for the treatment of hypertension and/or
Stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. Treatment should not be initiated with this combination.
Dosage and Administration:
Recommended treatment is one tablet per day as a single dose, preferably to be taken in the morning and before a meal.
In patients with a history of previous hypersensitivity to either of the active ingredients; perindopril or amlodipine, ACE inhibitors, dihydropyridines or excipient ingredients
During pregnancy and for lactating women.
Warnings and precautions:
Patients with diabetes.
Potassium sparing medicines, potassium supplements or potassium-containing salt.
Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis and haemodialysis
Anaphylactic reactions during desensitization
Dual blockade of the renin-angiotensin-aldosterone system (RAAS)
Aortic or mitral valve Stenosis / hypertrophic cardiomyopathy
Ancavaz contains perindopril arginine, an angiotensin-converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker.